The genetic tuning innovator adds pioneering genetic medicine expert and an accomplished biotechnology lawyer to its management team.DURHAM, N.C. & SEATTLE (BUSINESS WIRE) Today, leading epigenomic editing company Tune Therapeutics introduced two members to its leadership team: Chief Scientific Officer, Derek Jant.
Join us for this GEN webinar, where scientists from Codexis and Tune Therapeutics will highlight how engineered enzymes overcome common challenges with capping efficiency and dsRNA impurities in IVT manufacturing of mRNA required for vaccines and cell/gene therapeutics.
Up or Down: Chroma Medicine Raises Stakes in Epigenetic Editing genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
GV led Chroma Medicines Series B financing round, which the biotech will apply toward epigenetic medicines that could offer advantages over other editing technologies. Other recent financings include rounds from Cargo Therapeutics and Transcend Therapeutics.
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.